Catalent (CTLT) Rebounded from Low Post-COVID Valuations

Mairs & Power, an investment advisor, released “Mairs & Power Small Cap Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund was up 0.83% compared to a 2.57% return for the S&P Small Cap 600 TR benchmark and the Morningstar U.S. Fund Small Blend’s 3.17% return. In addition, please check the fund’s top five holdings to know its best picks in 2023.

Mairs & Power Small Cap Fund highlighted stocks like Catalent, Inc. (NYSE:CTLT) in its Q1 2023 investor letter. Headquartered in Somerset, New Jersey, Catalent, Inc. (NYSE:CTLT) is a drug, protein-based biologics, cell, and gene therapies manufacturer. On June 13, 2023, Catalent, Inc. (NYSE:CTLT) stock closed at $43.85 per share. One-month return of Catalent, Inc. (NYSE:CTLT) was 37.63%, and its shares lost 57.95% of their value over the last 52 weeks. Catalent, Inc. (NYSE:CTLT) has a market capitalization of $7.905 billion.

Mairs & Power Small Cap Fund made the following comment about Catalent, Inc. (NYSE:CTLT) in its first quarter 2023 investor letter:

“Catalent, Inc. (NYSE:CTLT), a New Jersey-based provider of services for manufacturing drugs, therapies, and consumer health products rebounded nicely from low post-COVID valuations and the prospects for a reacceleration of growth.”

Copyright: kadmy / 123RF Stock Photo

Catalent, Inc. (NYSE:CTLT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Catalent, Inc. (NYSE:CTLT) at the end of first quarter 2023 which was 31 in the previous quarter.

We discussed Catalent, Inc. (NYSE:CTLT) in another article and shared Aristotle Core Equity Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q1 2023 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

• 16 Least Profitable Industries in the US
• 15 Affordable Beachfront Retirement Communities
• 11 Best Hydrogen and Fuel Cell Stocks To Buy

Disclosure: None. This article is originally published at Insider Monkey.